EpiPen’s pricing debacle and its impact on patients, insurers

A firestorm erupted this week in response to the phar­ma­ceu­tical com­pany Mylan’s sharp increase in the price of its EpiPen, a life-​​saving treat­ment for severe allergic reac­tions. The com­pany quickly back­tracked, announcing a rebate plan. Here, three North­eastern fac­ulty members—pharmacist Tayla Rose, health­care finance expert Steven Pizer, and health policy researcher Gary Young—explain the clin­ical, eco­nomic, and policy impli­ca­tions of the controversy.

3Qs: From drug development to treating disease

Man­soor Amiji, dis­tin­guished pro­fessor and chair of phar­ma­ceu­tical sci­ences, tracks the drug dis­covery process, and ana­lyzes how the pur­suit of ‘block­buster’ drugs com­pares to treating patients with rare illnesses